Opus Genetics, Inc.
IRD
$2.05
$0.063.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.38% | 159.17% | 155.41% | 154.41% | -67.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.38% | 159.17% | 155.41% | 154.41% | -67.60% |
| Cost of Revenue | -28.65% | -1.05% | 66.37% | 65.56% | 176.62% |
| Gross Profit | 34.90% | 36.87% | -16.08% | -15.60% | -158.87% |
| SG&A Expenses | 72.11% | 71.91% | 37.06% | 123.55% | 40.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.09% | 24.87% | 51.81% | 101.28% | 114.02% |
| Operating Income | -3.77% | -6.94% | -28.81% | -84.73% | -225.41% |
| Income Before Tax | -131.92% | 4.44% | -15.31% | -632.44% | -235.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.92% | 4.44% | -15.31% | -632.74% | -235.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.92% | 4.44% | -15.31% | -632.74% | -235.34% |
| EBIT | -3.77% | -6.94% | -28.81% | -84.73% | -225.41% |
| EBITDA | -3.63% | -6.79% | -28.67% | -84.79% | -225.37% |
| EPS Basic | 14.17% | 61.06% | 16.56% | -455.06% | -211.03% |
| Normalized Basic EPS | 14.17% | 61.04% | 16.47% | -12.57% | -210.71% |
| EPS Diluted | 14.17% | 61.06% | 16.56% | -455.06% | -215.16% |
| Normalized Diluted EPS | 14.17% | 61.04% | 16.47% | -12.57% | -215.69% |
| Average Basic Shares Outstanding | 170.17% | 145.39% | 38.19% | 32.04% | 21.91% |
| Average Diluted Shares Outstanding | 170.17% | 145.39% | 38.19% | 32.04% | 16.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |